(Q73279454)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

title

Quantitative assessment of HER-2/neu protein concentration in breast cancer by enzyme-linked immunosorbent assay (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Quantitative Assessment of HER-2/Neu Protein Concentration in Breast Cancer by Enzyme-Linked Immunosorbent Assay (English)

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

24 December 2023

1 reference

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

24 December 2023

author name string

V. Müller

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

C. Thomssen

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

C. Karakas

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

I. Eustermann

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

J. Ramirez Porras

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

C. Coith

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

J. Berger

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

T. Löning

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

F. Jänicke

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

K. Pantel

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12699058

24 December 2023

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=12699058

24 December 2023

publication date

1 January 2003

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

The International Journal of Biological Markers

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

13-20

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

2 November 2019

cites work

1

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

24 December 2023

2

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

HER-2/neu oncogene protein and prognosis in breast cancer

24 December 2023

3

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry

24 December 2023

4

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Comparison of methods of measuring HER-2 in metastatic breast cancer patients treated with high-dose chemotherapy

24 December 2023

5

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.

24 December 2023

8

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

24 December 2023

9

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

24 December 2023

12

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

24 December 2023

13

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

The HER-2/neu oncogene in breast cancer: prognostic factor, predictive factor, and target for therapy.

24 December 2023

15

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

24 December 2023

16

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization

24 December 2023

17

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples

24 December 2023

20

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Detection of HER-2 oncogene amplification in breast cancer by differential polymerase chain reaction from single cryosections

24 December 2023

21

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Quantitative PCR analysis of c-erb B-2 (HER2/neu) gene amplification and comparison with p185(HER2/neu) protein expression in breast cancer drill biopsies

24 December 2023

22

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Detection of c-erbB-2 activation in paraffin-embedded tissue by immunohistochemistry

24 December 2023

23

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Optimization of immunohistochemical detection of ERBB2 in human breast cancer: impact of fixation

24 December 2023

26

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

24 December 2023

28

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients

24 December 2023

29

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Validation of a differential PCR and an ELISA procedure in studying HER-2/neu status in breast cancer.

24 December 2023

31

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts

24 December 2023

34

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

HER-2 and topo-isomerase IIalpha as predictive markers in a population of node-positive breast cancer patients randomly treated with adjuvant CMF or epirubicin plus cyclophosphamide

24 December 2023

35

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Clinical relevance of invasion factors urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 for individualized therapy decisions in primary breast cancer is greatest when used in combination

24 December 2023

36

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Chromogenic in situ hybridization analysis of HER-2/neu status in breast carcinoma: application in screening of patients for trastuzumab (Herceptin) therapy

24 December 2023

37

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

HER2 protein expression and gene amplification in androgen-independent prostate cancer

24 December 2023

38

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Evaluating HER2 amplification and overexpression in breast cancer.

24 December 2023

39

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

HER-2/neu in breast cancer: interobserver variability and performance of immunohistochemistry with 4 antibodies compared with fluorescent in situ hybridization.

24 December 2023

40

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification.

24 December 2023

41

1 reference

https://api.crossref.org/works/10.1177/172460080301800103

24 December 2023

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:12699058%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1 reference